• There are several AP binding sites in the sequence

  2024-01-26

  

  There are several AP-1 glucagon receptor in the sequence of TIMP-1 promoter [18,19]. EBV could up-regulate TIMP-1 expression by binding to the AP-1 site in the TIMP-1 promoter [18]. IL-32, a newly multi-function cytokine, could activate AP-1, NF-κβ, p38MAPK signal pathways, and induce cytokine expr

• Introduction Rapeseed oil production is very important

  2024-01-26

  

  Introduction Rapeseed oil production is very important not only because of its application in food industry, but also in petrochemical branch. Additionally, post-extraction meal and bagasse from oilseed rape are important sources of proteins in animal feedstuffs production. Oilseed rape (Brassica n

• br Concluding remarks Enhanced membrane binding upon calcium

  2024-01-26

  

  Concluding remarks Enhanced membrane binding upon calcium stimulation in PRX-08066 suggests a pre-requisite step that involves a conformational change in LOX. This might facilitate it to tether to the membrane and regulate enzyme activity. The calcium binding loops and the putative active site en

• Glu Gln Asp and Asn the main amino

  2024-01-26

  

  Glu, Gln, Asp, and Asn, the main parecoxib presented in the present study, are involved in nitrogen assimilation and transport processes within the plants. Furthermore, they are used to build up reserves during periods of nitrogen availability for subsequent use in growth, defense, and reproductive

• br Introduction There are greater than five million

  2024-01-26

  

  Introduction There are greater than five million Americans living with Alzheimer's dementia and more than 35 million people worldwide [1], and without a way to stop or slow the progression, there will be nearly a tripling of individuals affected by 2050 (13.8 million) [1]. The urgency to develop

• br Conclusion The HT receptor family is

  2024-01-26

  

  Conclusion The 5-HT receptor family is complex, and one may ask as does Bryan Roth et al. [205] whether this is useless Idelalisib (i.e. too much redundancy) or an embarrassment of the riches (i.e. many potential targets to choose from to affect normal or pathological function); molecular biology

• equol To our knowledge BAY has not progressed to clinical de

  2024-01-26

  

  To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit

• Tacrine an aminoacridine derivative Fig A was the

  2024-01-26

  

  Tacrine, an aminoacridine derivative (Fig. 1, A), was the first AChE inhibitor approved for treatment of AD [12], [13]. This compound was withdrawn from the market due to its hepatotoxicity [14]. In spite of tacrine's side effects, it is still an attractive lead compound for medicinal chemists due t

• Over the past decade extensive research has

  2024-01-25

  

  Over the past decade, extensive research has been directed toward the discovery of Aurora-selective small-molecule inhibitors. As a result, a handful of Aurora inhibitors has been identified. Among them, 1 (VX-680) and 2 (SNS-314) have entered human clinical trials as pan-Aurora kinase inhibitors (F

• Preliminary results of studies sponsored by

  2024-01-25

  

  Preliminary results of studies sponsored by the manufacturer of ETC-1002 have also shown positive results for monotherapy in statin-intolerant patients and for the combined use of the ACL inhibitor plus other cholesterol-reducing agents. In patients with a documented history of intolerance to statin

• The following are the supplementary data related to

  2024-01-25

  

  The following are the supplementary data related to this article. Competing interest Ethics approval and consent to participate Authors' contributions Acknowledgements The authors thank Dr. D. R. Kaplan for kind advice and materials derived from NB primary cell lines, Dr. F. D. Miller f

• br Materials and methods br Results and

  2024-01-25

  

  Materials and methods Results and discussion Conclusion Funding This work was supported by the Canadian Institute of Health Research (CIHR) [grant number FDN-148413] to PS, the National Science and Engineering Research Council of Canada (NSERC) [grant number CRD-399680] to ÉM, and the FR

• The increased occurrence of ARIA E in APOE carriers in

  2024-01-25

  

  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied

• br Material and methods br Results br Discussion

  2024-01-25

  

  Material and methods Results Discussion Although we were not able to detect 12/15-LOX mRNA in the lungs of 12/15-LOX knockout mice substantial amounts of 15-HETE could be detected in BALF. In fact, significant synthesis of 15-HETE in 12/15-LOX mice have been already reported [17]. The redun

• Initially DPP DPP and prolyl tripeptidyl peptidase A PtpA we

  2024-01-25

  

  Initially, DPP4, DPP7, and prolyl tripeptidyl peptidase A (PtpA) were the only exopeptidases identified in P. gingivalis. These share substrates according to their altered specificities, as DPP4 is highly specific for Pro at the penultimate position from the N-terminus (P1 position), though it accep

16281 records 198/1086 page Previous Next First page 上5页 196197198199200 下5页 Last page